Abstract
Dysregulated recruitment of leukocytes into the intestine is a characteristic feature of IBD. Several families of molecules regulate the influx of these cells into sites of inflammation within the gastrointestinal tract. Pharmacological blockade of interactions between molecules that mediate the formation of stable bonds (integrins) and their endothelial ligands has already shown clinical efficacy. Antibodies that target participant molecules have been approved by the US Federal Drug Administration for use in Crohn’s, multiple sclerosis (MS) (i.e. natalizumab) and psoriasis (i.e. efalizumab). A more recent additional family of drugs, which might also interfere with lymphocyte traffic (i.e. sphingosine-1- phosphate receptor agonists: fingolimod) is in clinical use for MS and just recently entered the clinical trial stage for ulcerative colitis. In the present review we discuss basic aspects of clinically relevant molecules and compile the clinical studies that support the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in IBD.
Keywords: Adhesion molecules, chemokines, Crohn’s disease, integrins, sphingosine1-phosphate, ulcerative colitis.
Current Drug Targets
Title:Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Volume: 14 Issue: 12
Author(s): Giorgos Bamias, David J. Clark and Jesús Rivera-Nieves
Affiliation:
Keywords: Adhesion molecules, chemokines, Crohn’s disease, integrins, sphingosine1-phosphate, ulcerative colitis.
Abstract: Dysregulated recruitment of leukocytes into the intestine is a characteristic feature of IBD. Several families of molecules regulate the influx of these cells into sites of inflammation within the gastrointestinal tract. Pharmacological blockade of interactions between molecules that mediate the formation of stable bonds (integrins) and their endothelial ligands has already shown clinical efficacy. Antibodies that target participant molecules have been approved by the US Federal Drug Administration for use in Crohn’s, multiple sclerosis (MS) (i.e. natalizumab) and psoriasis (i.e. efalizumab). A more recent additional family of drugs, which might also interfere with lymphocyte traffic (i.e. sphingosine-1- phosphate receptor agonists: fingolimod) is in clinical use for MS and just recently entered the clinical trial stage for ulcerative colitis. In the present review we discuss basic aspects of clinically relevant molecules and compile the clinical studies that support the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in IBD.
Export Options
About this article
Cite this article as:
Bamias Giorgos, Clark J. David and Rivera-Nieves Jesús, Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990158
DOI https://dx.doi.org/10.2174/13894501113149990158 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Overview of Immunotherapy in Alzheimer’s Disease (AD) and Mechanisms of IVIG Neuroprotection in Preclinical Models of AD)
Current Alzheimer Research Inactivation of Pathogenic Microorganisms by Photodynamic Techniques:Mechanistic Aspects and Perspective Applications.
Anti-Infective Agents in Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Withdrawal Notice: MMR Vaccine Susceptibility of Viral Agents Causing Meningitis and Meningoencephalitis in Children
Infectious Disorders - Drug Targets In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Current Pharmaceutical Design Strain Typing of Mycoplasma pneumoniae and its Value in Epidemiology
Current Pediatric Reviews Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Applications of Animal Models of Infectious Arthritis in Drug Discovery:A focus on Alphaviral Disease
Current Drug Targets Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Microneedle Patches as Drug and Vaccine Delivery Platform
Current Medicinal Chemistry Combining Drug and Immune Therapy: A Potential Solution to Drug Resistance and Challenges of HIV Vaccines?
Current HIV Research Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease
Current Alzheimer Research Therapeutic Applications of Peptides against Zika Virus: A Review
Current Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design